On the other hand, the suppression of enzymes that deplete ceramide—for instance, ceramidases, glucosylceramide synthase, or SphKs—when combined with standard cancer therapies that dysregulate these enzymes, reveal promising improvements in the patient response to various cancer therapies [38,39,40]. Here, UGCG is linked to cancer.